// App-Quantinova.ai

SAT0207 (2018) : Depressive symptoms in patients with rheumatoid arthritis in sarilumab target and mobility trials and impact of treatment

Researchers

Presenter

  • V. Strand

Principal Investigators

  • O. Hagino

  • S. Guillonneau

  • S. Boklage

  • M. Reaney

  • J. Sadeh

  • N. Narcisse

  • E. Mangan

  • T. Kirmura

Medical Centers

  • Stanford Univ, Palo Alto, CA

  • Sanofi Bridgewater NJ United States

  • Sanofi, Chilly-Mazarin, France

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.

  • RSCH, Guildford, United Kingdom

  • Ipsen, Boulogne-Billancourt, France

Locations

  • United States

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Central Nervous System (CNS)

Disease

  • Depression

  • Rheumatoid arthritis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Sarilumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • NA

Study Id's

  • NCT01061736

  • NCT01709578

Sponsors

  • Sanofi and Regeneron Pharmaceuticals

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved